Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Protagonist Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Protagonist Therapeutics, Inc.’s stock price such as:

• Protagonist Therapeutics, Inc.’s current stock price and volume
• Why Protagonist Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for PTGX from analysts
• PTGX’s stock price momentum as measured by its relative strength

About Protagonist Therapeutics, Inc. (PTGX)

Before we jump into Protagonist Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Want to learn more about Protagonist Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc.’s Stock Price as of Market Close

As of July 07, 2026, 2:30 PM, CST, Protagonist Therapeutics, Inc.’s stock price was $140.510.

Protagonist Therapeutics, Inc. is up 6.85% from its previous closing price of $131.500.

During the last market session, Protagonist Therapeutics, Inc.’s stock traded between $130.690 and $140.970. Currently, there are approximately 65.09 million shares outstanding for Protagonist Therapeutics, Inc..

Protagonist Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Protagonist Therapeutics, Inc. Stock Price History

Protagonist Therapeutics, Inc.’s (PTGX) price is currently up 14.63% so far this month.

During the month of July, Protagonist Therapeutics, Inc.’s stock price has reached a high of $140.970 and a low of $122.480.

Over the last year, Protagonist Therapeutics, Inc. has hit prices as high as $132.785 and as low as $49.380. Year to date, Protagonist Therapeutics, Inc.’s stock is up 60.88%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Protagonist Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 06, 2026,, no analysts have changed their rating of Protagonist Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Protagonist Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Protagonist Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Protagonist Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Protagonist Therapeutics, Inc. (PTGX) by visiting AAII Stock Evaluator.

Relative Price Strength of Protagonist Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 06, 2026, Protagonist Therapeutics, Inc. has a weighted four-quarter relative price strength of 19.38%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Protagonist Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Protagonist Therapeutics, Inc. Stock Price: Bottom Line

As of July 7, 2026, Protagonist Therapeutics, Inc.’s stock price is $140.510, which is up 6.85% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Protagonist Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.